 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| Jong-Mu Sun |
|
Precis Future Med. 2017;1(1):3-9. Published online March 31, 2017 DOI: https://doi.org/10.23838/pfm.2017.00066 |
|
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer Precision and Future Medicine. 2017;1(1):3-9  Personalized PD-1/PD-L1 inhibitor therapy for advanced non small cell lung cancer beyond first line; a meta-analysis of potential predictive factors Annals of Oncology. 2016;27:vi373 Network Meta-Analysis of First-Line Immune Checkpoint Inhibitor Therapy in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with PD-L1 Expression ≥50% . 2023; Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50% BMC Cancer. 2023;23(1): Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer Frontiers in Oncology. 2020;10: 406P Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis Annals of Oncology. 2020;31:S1401 First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective Lung Cancer. 2018;123:166-171 First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers Journal of Cancer Research and Clinical Oncology. 2019;146(2):441-448 Use of PD-L1 Biomarker in Second Line Therapy for Non-Small Cell Lung Cancer: Budget Impact Analysis from a Private Payer Perspective In Brazil Value in Health. 2018;21:S23 1119P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer Annals of Oncology. 2022;33:S1063 |
